Unraveling Metabolic Regulation in Aneuploid Tumor Cells: Key Insights for Targeted Cancer Therapies
A research team led by Professor YANG Zhenye from the Division of Life Sciences and Medicine, the University of Science and Technology of China (USTC) of Chinese Academy of Sciences (CAS), in collaboration with Associate Researcher GUO Jing from the First Affiliated Hospital of USTC, has made significant progress in the field of metabolic regulation during the mitotic phase of aneuploid tumor cells. Their research findings, titled A mitotic NADPH upsurge promotes chromosome segregation and tumor progression in aneuploid cancer cells, were published online on June 22, 2023, in the journal Nature Metabolism.
Aneuploidy, characterized by an abnormal number of chromosomes in tumor cells, is the most common feature observed in human cancer cells. More than 85% of tumor genomes are aneuploid, while normal cells are diploid. Finding specific targets for aneuploid tumors is an effective strategy to precisely kill cancer cells without affecting normal diploid cells. However, the mechanisms by which aneuploid tumor cells successfully cope with the dual pressures of oxidative stress and mitosis during cell division are not yet fully understood.
The research team employed live-cell probes for metabolites, cellular and animal models, as well as the analysis of clinical sample cohorts, to delve into the dynamic changes and regulatory mechanisms of redox metabolism in aneuploid tumor cells during the mitotic phase. They discovered the crucial role and significance of the core metabolite nicotinamide adenine dinucleotide phosphate (NADPH) during the mitotic phase of the cell cycle, demonstrating that this metabolic regulation ensures accurate chromosome segregation and maintenance of genomic integrity in aneuploid tumor cells. The study provided a comprehensive understanding of the upstream regulation of NADPH during mitosis, involving the kinase CDK1/AMPK, which phosphorylates the co-chaperone molecule BAG3-T285, leading to the release and activation of the metabolic enzyme G6PD.
Additionally, downstream metabolic and cell cycle signals involved in chromosome segregation regulation were identified. The study also found that the phosphorylation of BAG3-T285 was significantly higher in microsatellite-stable (mostly aneuploid) colorectal cancer samples, and was associated with poor prognosis. These findings provide new biomarkers and treatment strategies for selectively inhibiting aneuploid tumors by intervening in metabolic pathways.
The research sheds light on the metabolic regulation of aneuploid tumor cells during the mitotic phase. Their findings not only deepen our understanding of the mechanisms behind aneuploidy but also provide potential targets for the development of novel therapies against aneuploid tumors. This breakthrough contributes to the ongoing efforts in precision medicine and personalized cancer treatment.
Paper Link：https://doi.org/10.1038/s42255-023-00848-1
(Written by QIU Rong, Edited by MA Xuange , USTC News Center)
A research team led by Professor YANG Zhenye from the Division of Life Sciences and Medicine, the University of Science and Technology of China (USTC) of Chinese Academy of Sciences (CAS), in collaboration with Associate Researcher GUO Jing from the First Affiliated Hospital of USTC, has made significant progress in the field of metabolic regulation during the mitotic phase of aneuploid tumor cells. Their research findings, titled "A mitotic NADPH upsurge promotes chromosome segregation and tumor progression in aneuploid cancer cells," were published online on June 22, 2023, in the journal Nature Metabolism.
Aneuploidy, characterized by an abnormal number of chromosomes in tumor cells, is the most common feature observed in human cancer cells. More than 85% of tumor genomes are aneuploid, while normal cells are diploid. Finding specific targets for aneuploid tumors is an effective strategy to precisely kill cancer cells without affecting normal diploid cells. However, the mechanisms by which aneuploid tumor cells successfully cope with the dual pressures of oxidative stress and mitosis during cell division are not yet fully understood.
The research team employed live-cell probes for metabolites, cellular and animal models, as well as the analysis of clinical sample cohorts, to delve into the dynamic changes and regulatory mechanisms of redox metabolism in aneuploid tumor cells during the mitotic phase. They discovered the crucial role and significance of the core metabolite nicotinamide adenine dinucleotide phosphate (NADPH) during the mitotic phase of the cell cycle, demonstrating that this metabolic regulation ensures accurate chromosome segregation and maintenance of genomic integrity in aneuploid tumor cells. The study provided a comprehensive understanding of the upstream regulation of NADPH during mitosis, involving the kinase CDK1/AMPK, which phosphorylates the co-chaperone molecule BAG3-T285, leading to the release and activation of the metabolic enzyme G6PD.
Additionally, downstream metabolic and cell cycle signals involved in chromosome segregation regulation were identified. The study also found that the phosphorylation of BAG3-T285 was significantly higher in microsatellite-stable (mostly aneuploid) colorectal cancer samples, and was associated with poor prognosis. These findings provide new biomarkers and treatment strategies for selectively inhibiting aneuploid tumors by intervening in metabolic pathways.
The research sheds light on the metabolic regulation of aneuploid tumor cells during the mitotic phase. Their findings not only deepen our understanding of the mechanisms behind aneuploidy but also provide potential targets for the development of novel therapies against aneuploid tumors. This breakthrough contributes to the ongoing efforts in precision medicine and personalized cancer treatment.
Paper Link：https://doi.org/10.1038/s42255-023-00848-1
(Written by QIU Rong, Edited by MA Xuange , USTC News Center)
Back